Collplant Holdings (CLGN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CollPlant Biotechnologies has reported promising pre-clinical results for its innovative 3D-printed regenerative breast implants, designed to address a $3 billion market. Despite a decline in revenue, the company is actively pursuing collaborations to leverage its rhCollagen technology, aiming to enhance its financial position and advance its development programs.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.